<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03268135</url>
  </required_header>
  <id_info>
    <org_study_id>RNA-HF-AS</org_study_id>
    <nct_id>NCT03268135</nct_id>
  </id_info>
  <brief_title>Heart Failure and Aortic Stenosis Transcriptome</brief_title>
  <acronym>RNA-HF-AS</acronym>
  <official_title>Study of the Transcriptomic Alterations in Heart Failure and Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Donato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to investigate the global transcriptome in order to determine the&#xD;
      expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro&#xD;
      noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to&#xD;
      clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers.&#xD;
      To this purpose, both tissue and blood specimens will be collected and patients will be&#xD;
      compared to individuals not affected by cardiovascular diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will collect plasma and cardiac tissue specimens from consenting subjects.&#xD;
      The investigators will evaluate the expression of mRNAs, miRNAs and lncRNAs in patients&#xD;
      affected by both end-stage and not end-stage HF as well as in patients affected by aortic&#xD;
      stenosis and undergoing valve replacement and requiring cardiac myectomy. The tissue&#xD;
      dysregulated RNAs will be next measured in plasma samples in order to clarify their potential&#xD;
      as biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac tissutal mRNAs signatures</measure>
    <time_frame>from Year 1 to Year 3</time_frame>
    <description>The mRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac tissutal miRNAs signatures</measure>
    <time_frame>from Year 1 to Year 3</time_frame>
    <description>The miRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac tissutal lncRNAs signatures</measure>
    <time_frame>from Year 1 to Year 3</time_frame>
    <description>The lncRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non end-stage, end-stage heart failure, aortic stenosis mRNAs signatures in plasmas</measure>
    <time_frame>from Year 3 to Year 5</time_frame>
    <description>The mRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non end-stage, end-stage heart failure, aortic stenosis miRNAs signatures in plasmas</measure>
    <time_frame>from Year 3 to Year 5</time_frame>
    <description>The miRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non end-stage, end-stage heart failure, aortic stenosis lncRNAs signatures in plasmas</measure>
    <time_frame>from Year 3 to Year 5</time_frame>
    <description>The lncRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Non end-stage heart failure</arm_group_label>
    <description>Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End-stage heart failure</arm_group_label>
    <description>Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic Stenosis</arm_group_label>
    <description>Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Measurement of RNAs in individuals not affected by cardiovascular diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>measurement of RNAs</intervention_name>
    <arm_group_label>Aortic Stenosis</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>End-stage heart failure</arm_group_label>
    <arm_group_label>Non end-stage heart failure</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cardiac tissue and blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cardiac surgery patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non end-stage heart failure&#xD;
&#xD;
               -  left ventricle restoration surgery (SVR)&#xD;
&#xD;
               -  End Systolic Volume Index (ESVI) &gt;35 ml/m2&#xD;
&#xD;
               -  Ejection Fraction (EF)&lt;40%&#xD;
&#xD;
               -  previous transmural anterior myocardial infarction (MI)&#xD;
&#xD;
               -  age: 40-75&#xD;
&#xD;
          2. End-stage heart failure&#xD;
&#xD;
               -  left ventricle assisted device (LVAD) surgery&#xD;
&#xD;
               -  age: 40-75&#xD;
&#xD;
               -  Ejection Fraction (EF) &lt;25%&#xD;
&#xD;
               -  End Systolic Volume Index (ESVI)≥60 ml/m2&#xD;
&#xD;
          3. Aortic Stenosis&#xD;
&#xD;
               -  aortic valve replacement&#xD;
&#xD;
               -  intracardial pressure difference &gt;40 mmHg&#xD;
&#xD;
               -  septal diameter ≥1.3 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non end-stage heart failure&#xD;
&#xD;
               -  End Systolic Volume Index (ESVI)&lt;35 ml/m2&#xD;
&#xD;
               -  Ejection Fraction (EF)&gt;40%&#xD;
&#xD;
               -  Time from MI unknown&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Other genetic diseases&#xD;
&#xD;
               -  Neoplasms&#xD;
&#xD;
               -  Collagenopathies&#xD;
&#xD;
               -  Chemo/radiotherapy&#xD;
&#xD;
               -  Prolonged use of corticosteroids&#xD;
&#xD;
               -  Infections&#xD;
&#xD;
               -  Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and&#xD;
                  Hepatitis C Virus (HCV) positive&#xD;
&#xD;
          2. End-stage heart failure&#xD;
&#xD;
               -  EF&gt;25%&#xD;
&#xD;
               -  Time from MI unknown&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Other genetic diseases&#xD;
&#xD;
               -  Neoplasms&#xD;
&#xD;
               -  Collagenopathies&#xD;
&#xD;
               -  Chemo/radiotherapy&#xD;
&#xD;
               -  Prolonged use of corticosteroids&#xD;
&#xD;
               -  Infections&#xD;
&#xD;
               -  Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and&#xD;
                  Hepatitis C Virus (HCV) positive&#xD;
&#xD;
          3. Aortic Stenosis&#xD;
&#xD;
               -  coronaropathies&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Other genetic diseases&#xD;
&#xD;
               -  Neoplasms&#xD;
&#xD;
               -  Collagenopathies&#xD;
&#xD;
               -  Chemo/radiotherapy&#xD;
&#xD;
               -  Prolonged use of corticosteroids&#xD;
&#xD;
               -  Infections&#xD;
&#xD;
               -  Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and&#xD;
                  Hepatitis C Virus (HCV) positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Martelli, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS-POLICLINICO SAN DONATO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Martelli, Dr</last_name>
    <phone>+39 02 26437762</phone>
    <email>fabio.martelli@grupposandonato.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Irccs Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milan</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FABIO MARTELLI, PhD</last_name>
      <phone>0252774683</phone>
      <email>fabio.martelli@grupposandonato.it</email>
    </contact>
    <investigator>
      <last_name>LORENZO MENICANTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SIMONA GRECO, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SERENELLA CASTELVECCHIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele De Bonis, MD, PhD</last_name>
      <email>debonis.michele@hsr.it</email>
    </contact>
    <investigator>
      <last_name>MICHELE DE BONIS, MD FESC FAHA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Donato</investigator_affiliation>
    <investigator_full_name>Fabio Martelli</investigator_full_name>
    <investigator_title>Dr, PhD, Molecular Cardiology Laboratory Director</investigator_title>
  </responsible_party>
  <keyword>miRNA</keyword>
  <keyword>lncRNAs</keyword>
  <keyword>transcriptome</keyword>
  <keyword>heart failure</keyword>
  <keyword>aortic stenosis</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

